Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc (NYSE: BAX) is a global healthcare leader specializing in life-saving renal care, advanced medical devices, and hospital solutions. This page provides investors and healthcare professionals with timely updates on the company’s operational developments, regulatory milestones, and strategic initiatives.
Access authoritative information about Baxter’s latest financial results, product innovations, and partnerships. Our curated news collection simplifies tracking of critical updates across key areas including dialysis technologies, infusion systems, and biosurgery products.
Discover official announcements regarding:
• Quarterly earnings and financial guidance
• New product approvals and clinical trials
• Strategic acquisitions in medical technology
• Regulatory compliance updates
• Leadership changes and corporate governance
Bookmark this page for streamlined access to Baxter’s verified news developments. Check regularly for updates that may impact market positioning and healthcare sector trends.
Baxter International Inc. (NYSE:BAX) reported first-quarter 2023 revenue of $3.65 billion, a 2% decrease year-over-year on a reported basis but a 2% increase on a constant currency basis. U.S. GAAP earnings per share (EPS) were $0.09, while adjusted EPS was $0.59. For 2023, Baxter anticipates sales growth of 1% to 2% and U.S. GAAP EPS between $1.16 and $1.31, with adjusted EPS between $2.85 and $3.00. Key drivers for sales included Advanced Surgery and Pharmaceuticals, though declines were noted in Acute Therapies and Patient Support Systems. The company is also advancing a strategic spinoff of its Kidney Care segment, expected to occur by July 2024. Innovation efforts include launching the Novum IQ and ExactaMix Pro systems, aimed at enhancing patient care and operational efficiency.